TITLE

OncoMed Completes $154M Round

AUTHOR(S)
Schachter, Ken
PUB. DATE
November 2008
SOURCE
Red Herring;11/4/2008, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the completion of the $154 million venture capital fund raising of cancer stem cell researcher OncoMed Pharmaceuticals. Paul Hastings, OncoMed chief executive, claims that the funds they raised would enable OncoMed to take two cancer stem cell antibody therapeutics through phase II clinical trials, as well as to expand its monoclonal antibody pipeline. The $154 million venture funding raised by OncoMed overshadows the top round in the third quarter of 2008, a $140 million financing for alternative energy provider SolarReserve.
ACCESSION #
36586106

 

Related Articles

  • Seeking a cure.  // Smart Business Northern California;Jul2009, Vol. 2 Issue 8, ps8 

    The article profiles Paul Hastings, Paul J. Hastings, president and chief executive officer (CEO) of OncoMed Pharmaceuticals Inc. in the U.S. He is a finalist in the 2009 Ernst & Young Entrepreneur of the Year awards. He intended to create a therapy for the treatment of cancer and in 2008,...

  • Alternative financing. Bonny, Dominick // Wenatchee Business Journal;Sep2010, Vol. 24 Issue 9, p20 

    The article discusses alternative ways in securing capital to expand or start a new business in Washington. It states that there are alternatives to traditional lending which are beneficial to some Wenatchee Valley businesses. Among the options include state and federal grants and loans, venture...

  • VENTURE CAPITAL FIRMS ARE BACKING THE RENEWABLE ENERGY INNOVATORS.  // In Business;Nov/Dec2004, Vol. 26 Issue 6, p4 

    The article focuses on recent reports that shows an increasing involvement of venture capital investors in entrepreneurial companies breaking new ground in renewable energy technologies. According to CEO Bruce Woodry of the Sigma Capital Group in Harbor Springs, Michigan, their company is...

  • Fourth-Quarter Venture Funding Plunged. Daks, Martin C. // njbiz;2/2/2009, Vol. 22 Issue 5, p5 

    The article reports a decline in venture investment by more than 50 percent in the fourth quarter of 2008 as 24 New Jersey companies got a total of $134.5 million. According to the latest MoneyTree Report provided by PricewaterhouseCoopers and the National Venture Capital Association, the fourth...

  • Antibody Deal With GSK Netting OncoMed $1.4B.  // Bioworld Week;12/17/2007, Vol. 15 Issue 51, p3 

    The article reports on the deal between OncoMed Pharmaceuticals Inc. and GlaxoSmithKline for the discovery, development and commercialization of antibodies targeting cancer stem cells. Under the agreement, OncoMed will receive an upfront payment composed of cash and equity as well as potential...

  • Long Road Ahead for Biotechs In Quest for Venture Capital. Winter, Peter // BioWorld Insight;1/ 7/2013, Vol. 21 Issue 2, p2 

    The article reports on the challenges faced by biopharmaceutical companies in search for venture capital in 2012 to fuel their product programs. It projects a tough fundraising program for chief executive officers (CEOs) due to the market contraction since the first quarter of 2012. Association...

  • 10 STUPID THINGS VCs DO! Manchanda, Supreet // Siliconindia;Mar2001, Vol. 5 Issue 3, p102 

    Provides tips on venture capital. Challenges for venture capitalists and entrepreneurs; Effect of market changes on businesses; Responsibilities of chief executive officers.

  • Hello, It's Me: VCs Once Again Wooing Biopharm Companies. O'Connell, Brian // BioPharm International;Apr2005, Vol. 18 Issue 4, p18 

    Focuses on the basis of successful investment of venture capital (VC) firms from billionaire financier Warren Buffet's rule in the biopharm industry in Nebraska. Launch of new initial public offering by the biopharm industry; Comments from senior managing partner with Peseus-Soros Management LLC...

  • Cerenis: Bring home $83.5M. Dietderich, Andrew // Crain's Detroit Business;4/23/2007, Vol. 23 Issue 17, Special section p22 

    The article presents information related to Cerenis Therapeutics Inc. The company develops drugs that boost levels of high-density lipoprotein or HDL, the good cholesterol that helps rid the human body of bad cholesterol, called low-density lipoprotein or LDL, that causes cardiovascular disease....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics